vs
Side-by-side financial comparison of Alaunos Therapeutics, Inc. (TCRT) and Whitehawk Therapeutics, Inc. (WHWK). Click either name above to swap in a different company.
Over the past eight quarters, Alaunos Therapeutics, Inc.'s revenue compounded faster (73.2% CAGR vs -100.0%).
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) immunotherapies for the treatment of hard-to-treat solid tumors. The firm focuses on advancing precision oncology candidates targeting shared tumor antigens, serving global oncology patient populations via internal R&D and cross-sector partnerships.
TCRT vs WHWK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.0K | $0 |
| Net Profit | — | $-23.3M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | -40.0% | — |
| Net Profit YoY | -20.5% | -27.2% |
| EPS (diluted) | — | $-1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0K | $0 | ||
| Q3 25 | $0 | $0 | ||
| Q2 25 | $0 | $0 | ||
| Q1 25 | $2.0K | $7.1M | ||
| Q4 24 | $5.0K | $7.2M | ||
| Q3 24 | $0 | $7.2M | ||
| Q2 24 | $4.0K | $6.2M | ||
| Q1 24 | $1.0K | $5.4M |
| Q4 25 | — | $-23.3M | ||
| Q3 25 | $-1.2M | $-17.7M | ||
| Q2 25 | $-1.1M | $-52.6M | ||
| Q1 25 | $-1.1M | $73.0M | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | $-1.1M | $-12.5M | ||
| Q2 24 | $-1.1M | $-14.6M | ||
| Q1 24 | $-1.7M | $-18.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 89.4% | ||
| Q4 24 | — | 89.1% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | — | 87.4% | ||
| Q1 24 | — | 87.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -54600.0% | -213.0% | ||
| Q4 24 | — | -261.8% | ||
| Q3 24 | — | -186.0% | ||
| Q2 24 | -29150.0% | -252.2% | ||
| Q1 24 | -174200.0% | -364.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -53650.0% | 1021.9% | ||
| Q4 24 | — | -252.4% | ||
| Q3 24 | — | -174.0% | ||
| Q2 24 | -28225.0% | -236.0% | ||
| Q1 24 | -168200.0% | -341.7% |
| Q4 25 | — | $-1.14 | ||
| Q3 25 | $-0.55 | $-0.26 | ||
| Q2 25 | $-0.63 | $-0.76 | ||
| Q1 25 | $-0.67 | $1.83 | ||
| Q4 24 | — | $-0.68 | ||
| Q3 24 | $-0.70 | $-0.46 | ||
| Q2 24 | $-0.71 | $-0.54 | ||
| Q1 24 | $-1.05 | $-0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4M | $145.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2M | $136.3M |
| Total Assets | $3.0M | $150.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4M | $145.7M | ||
| Q3 25 | $1.9M | $162.6M | ||
| Q2 25 | $2.9M | $177.2M | ||
| Q1 25 | $319.0K | $231.1M | ||
| Q4 24 | $1.1M | $47.2M | ||
| Q3 24 | $1.7M | $62.6M | ||
| Q2 24 | $2.5M | $78.6M | ||
| Q1 24 | $4.1M | $88.3M |
| Q4 25 | $2.2M | $136.3M | ||
| Q3 25 | $2.8M | $157.2M | ||
| Q2 25 | $3.7M | $172.1M | ||
| Q1 25 | $1.1M | $221.7M | ||
| Q4 24 | $2.1M | $52.5M | ||
| Q3 24 | $2.7M | $68.9M | ||
| Q2 24 | $3.8M | $78.8M | ||
| Q1 24 | $4.8M | $90.5M |
| Q4 25 | $3.0M | $150.8M | ||
| Q3 25 | $3.7M | $167.0M | ||
| Q2 25 | $4.7M | $180.8M | ||
| Q1 25 | $2.1M | $234.0M | ||
| Q4 24 | $2.8M | $70.3M | ||
| Q3 24 | $3.5M | $85.7M | ||
| Q2 24 | $4.7M | $101.6M | ||
| Q1 24 | $6.0M | $111.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $-17.2M |
| Free Cash FlowOCF − Capex | $-3.0M | — |
| FCF MarginFCF / Revenue | -98900.0% | — |
| Capex IntensityCapex / Revenue | 3266.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $-17.2M | ||
| Q3 25 | $-844.0K | $-15.4M | ||
| Q2 25 | $-701.0K | $-53.0M | ||
| Q1 25 | $-772.0K | $-11.9M | ||
| Q4 24 | $-5.0M | $-15.1M | ||
| Q3 24 | $-781.0K | $-15.7M | ||
| Q2 24 | $-1.7M | $-9.2M | ||
| Q1 24 | $-1.9M | $-19.7M |
| Q4 25 | $-3.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-53.0M | ||
| Q1 25 | — | $-12.4M | ||
| Q4 24 | — | $-15.2M | ||
| Q3 24 | — | $-15.9M | ||
| Q2 24 | — | $-9.7M | ||
| Q1 24 | — | $-20.4M |
| Q4 25 | -98900.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -173.8% | ||
| Q4 24 | — | -210.5% | ||
| Q3 24 | — | -220.1% | ||
| Q2 24 | — | -157.0% | ||
| Q1 24 | — | -380.9% |
| Q4 25 | 3266.7% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | 0.0% | 2.6% | ||
| Q3 24 | — | 2.6% | ||
| Q2 24 | 0.0% | 8.8% | ||
| Q1 24 | 0.0% | 13.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.16× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
